The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

The U.S. Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above, ...

As the World Health Organization initiates a new agreement for coordinating global responses to future pandemics, the future ...

Novavax, Inc. (“Novavax”) announced that FDA approved its Biologics License Application (“BLA”) for Nuvaxovid™ for active ...

The US FDA has approved Moderna's next-generation COVID-19 vaccine, mNEXSPIKE, for use in adults aged 65 and older.

The shot, dubbed mNexspike, is approved for older adults and people whose health conditions put them at higher risk of severe ...

Novavax, Inc. (Nasdaq: NVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Nuvaxovid™ for active immunization to ...

Moderna Covid vaccine approved for those 12-64 with risk factors Moderna expects mNEXSPIKE to be ready for 2025-2026 season ...

In a video posted to social media on Tuesday, HHS Secretary Robert F. Kennedy, Jr. claimed that there is a lack of clinical ...